Desperate pancreatic cancer patients offered experimental Two-Drug combo
NCT ID NCT07175389
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial will test a combination of two drugs—JDB153 (taken as a pill) and serplulimab (given by IV)—in 10 people with advanced pancreatic cancer that has not responded to standard treatments. The main goals are to check safety and see if the drugs can shrink tumors. Because it is a small, early study, it is too soon to know if this approach will work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JDB153 (oral drug) and serplulimab (intravenous immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for pancreatic cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early, small trial (only 10 people) testing safety first. The combination may not shrink tumors or improve survival, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact